OptiNose (NASDAQ:OPTN - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect OptiNose to post earnings of ($0.74) per share and revenue of $17.70 million for the quarter.
OptiNose (NASDAQ:OPTN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.67. The company had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.02 million. On average, analysts expect OptiNose to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
OptiNose Stock Performance
OPTN stock remained flat at $9.39 during trading on Friday. 8,064 shares of the company were exchanged, compared to its average volume of 59,589. The firm has a market cap of $95.09 million, a P/E ratio of -2.24 and a beta of -0.88. OptiNose has a one year low of $4.82 and a one year high of $20.03. The business has a fifty day simple moving average of $8.39 and a 200-day simple moving average of $7.50.
Insider Transactions at OptiNose
In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the transaction, the chief executive officer now directly owns 126,931 shares of the company's stock, valued at approximately $671,464.99. The trade was a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 8,213 shares of company stock worth $43,643 over the last quarter. 2.30% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
OPTN has been the subject of a number of research analyst reports. HC Wainwright restated a "neutral" rating and issued a $9.00 target price (down previously from $18.00) on shares of OptiNose in a research note on Friday, March 21st. Piper Sandler reaffirmed a "neutral" rating and set a $9.00 target price (down previously from $15.00) on shares of OptiNose in a report on Friday, March 21st. Finally, Lake Street Capital downgraded shares of OptiNose from a "buy" rating to a "hold" rating and cut their price target for the stock from $17.00 to $9.00 in a report on Thursday, March 20th.
Read Our Latest Stock Analysis on OPTN
OptiNose Company Profile
(
Get Free Report)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
Featured Articles

Before you consider OptiNose, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptiNose wasn't on the list.
While OptiNose currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.